CHRS

Over the past six months, several events have impacted Coherus Oncology's stock price. Coherus closed an underwritten public offering of 28.6 million shares of common stock at $1.75 per share on February 17, 2026. On March 9, 2026, Coherus Oncology reported its full-year and fourth-quarter 2025 financial results, with LOQTORZI net revenue more than doubling in 2025. On November 6, 2025, Coherus reported its third-quarter 2025 financial results, with LOQTORZI net revenue increasing by 92% over Q3 2024. On September 5, 2025, Coherus announced it had regained compliance with Nasdaq's minimum bid price requirement. On May 12, 2025, Coherus reported Q1 2025 financial results, with LOQTORZI net product sales of $7.3 million. The company's share price has been highly volatile over the past three months.